Ani Pharmaceuticals (ANIP) Cash from Investing Activities (2010 - 2026)

Ani Pharmaceuticals has reported Cash from Investing Activities for 17 years, with the latest figure at -$11.3 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 42.94% year-over-year to -$11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.8 million (up 94.05% YoY) and the FY2025 annual result came in at -$34.3 million, up 91.52% from the prior year.
• Cash from Investing Activities eased to -$11.3 million in Q1 2026 per ANIP's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $8.9 million in Q1 2024 and troughed at -$398.5 million in Q3 2024.
• A 5-year average of -$28.5 million and a median of -$4.8 million in 2023 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 479.64% in 2024, down 8652.95% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$3.1 million in 2022, then sank by 52.1% to -$4.8 million in 2023, then plunged by 123.5% to -$10.7 million in 2024, then surged by 86.86% to -$1.4 million in 2025, then plunged by 707.13% to -$11.3 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$11.3 million, -$1.4 million, and -$6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.